Annual EBITDA
-$99.25 M
-$33.22 M-50.31%
December 31, 2023
Summary
- As of February 26, 2025, KZR annual EBITDA is -$99.25 million, with the most recent change of -$33.22 million (-50.31%) on December 31, 2023.
- During the last 3 years, KZR annual EBITDA has fallen by -$59.06 million (-146.91%).
- KZR annual EBITDA is now -1057.62% below its all-time high of -$8.57 million, reached on December 31, 2017.
Performance
KZR EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$19.65 M
+$1.24 M+5.91%
September 30, 2024
Summary
- As of February 26, 2025, KZR quarterly EBITDA is -$19.65 million, with the most recent change of +$1.24 million (+5.91%) on September 30, 2024.
- Over the past year, KZR quarterly EBITDA has stayed the same.
- KZR quarterly EBITDA is now -969.10% below its all-time high of -$1.84 million, reached on June 30, 2017.
Performance
KZR Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$93.11 M
+$2.78 M+2.90%
September 30, 2024
Summary
- As of February 26, 2025, KZR TTM EBITDA is -$93.11 million, with the most recent change of +$2.78 million (+2.90%) on September 30, 2024.
- Over the past year, KZR TTM EBITDA has stayed the same.
- KZR TTM EBITDA is now -4107.59% below its all-time high of -$2.21 million, reached on March 31, 2017.
Performance
KZR TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
KZR EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -50.3% | 0.0% | 0.0% |
| 3 y3 years | -146.9% | 0.0% | 0.0% |
| 5 y5 years | -312.9% | 0.0% | 0.0% |
KZR EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -87.4% | at low | -43.8% | +37.8% | -75.8% | +6.2% |
| 5 y | 5-year | -193.8% | at low | -165.5% | +37.8% | -175.6% | +6.2% |
| alltime | all time | -1057.6% | at low | -969.1% | +37.8% | -4107.6% | +6.2% |
Kezar Life Sciences EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$19.65 M(-5.9%) | -$93.11 M(-2.9%) |
| Jun 2024 | - | -$20.89 M(-0.5%) | -$95.89 M(-2.8%) |
| Mar 2024 | - | -$21.00 M(-33.5%) | -$98.68 M(-0.6%) |
| Dec 2023 | -$99.25 M(+50.3%) | -$31.58 M(+40.8%) | -$99.25 M(+16.1%) |
| Sep 2023 | - | -$22.43 M(-5.3%) | -$85.50 M(+6.7%) |
| Jun 2023 | - | -$23.67 M(+9.8%) | -$80.16 M(+11.4%) |
| Mar 2023 | - | -$21.57 M(+21.0%) | -$71.97 M(+9.5%) |
| Dec 2022 | -$66.03 M(+24.7%) | -$17.83 M(+4.4%) | -$65.75 M(+6.8%) |
| Sep 2022 | - | -$17.08 M(+10.3%) | -$61.58 M(+5.1%) |
| Jun 2022 | - | -$15.48 M(+0.9%) | -$58.59 M(+5.2%) |
| Mar 2022 | - | -$15.35 M(+12.3%) | -$55.69 M(+5.2%) |
| Dec 2021 | -$52.96 M(+31.8%) | -$13.67 M(-3.0%) | -$52.96 M(+8.6%) |
| Sep 2021 | - | -$14.08 M(+11.9%) | -$48.79 M(+6.5%) |
| Jun 2021 | - | -$12.59 M(-0.3%) | -$45.81 M(+7.3%) |
| Mar 2021 | - | -$12.62 M(+33.0%) | -$42.70 M(+6.2%) |
| Dec 2020 | -$40.20 M | -$9.49 M(-14.5%) | -$40.20 M(+5.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | -$11.11 M(+17.1%) | -$38.11 M(+4.8%) |
| Jun 2020 | - | -$9.48 M(-6.2%) | -$36.35 M(+1.3%) |
| Mar 2020 | - | -$10.12 M(+36.7%) | -$35.90 M(+6.2%) |
| Dec 2019 | -$33.79 M(+40.6%) | -$7.40 M(-20.8%) | -$33.79 M(+3.6%) |
| Sep 2019 | - | -$9.35 M(+3.5%) | -$32.61 M(+11.2%) |
| Jun 2019 | - | -$9.03 M(+12.8%) | -$29.32 M(+8.4%) |
| Mar 2019 | - | -$8.01 M(+28.7%) | -$27.04 M(+12.5%) |
| Dec 2018 | -$24.04 M(+180.3%) | -$6.22 M(+2.7%) | -$24.04 M(+19.1%) |
| Sep 2018 | - | -$6.06 M(-10.3%) | -$20.19 M(+24.0%) |
| Jun 2018 | - | -$6.76 M(+35.1%) | -$16.28 M(+43.3%) |
| Mar 2018 | - | -$5.00 M(+110.6%) | -$11.36 M(+32.5%) |
| Dec 2017 | -$8.57 M(-3.0%) | -$2.37 M(+10.5%) | -$8.57 M(+38.3%) |
| Sep 2017 | - | -$2.15 M(+16.9%) | -$6.20 M(+53.0%) |
| Jun 2017 | - | -$1.84 M(-16.9%) | -$4.05 M(+83.1%) |
| Mar 2017 | - | -$2.21 M | -$2.21 M |
| Dec 2016 | -$8.84 M | - | - |
FAQ
- What is Kezar Life Sciences annual EBITDA?
- What is the all time high annual EBITDA for Kezar Life Sciences?
- What is Kezar Life Sciences annual EBITDA year-on-year change?
- What is Kezar Life Sciences quarterly EBITDA?
- What is the all time high quarterly EBITDA for Kezar Life Sciences?
- What is Kezar Life Sciences quarterly EBITDA year-on-year change?
- What is Kezar Life Sciences TTM EBITDA?
- What is the all time high TTM EBITDA for Kezar Life Sciences?
- What is Kezar Life Sciences TTM EBITDA year-on-year change?
What is Kezar Life Sciences annual EBITDA?
The current annual EBITDA of KZR is -$99.25 M
What is the all time high annual EBITDA for Kezar Life Sciences?
Kezar Life Sciences all-time high annual EBITDA is -$8.57 M
What is Kezar Life Sciences annual EBITDA year-on-year change?
Over the past year, KZR annual EBITDA has changed by -$33.22 M (-50.31%)
What is Kezar Life Sciences quarterly EBITDA?
The current quarterly EBITDA of KZR is -$19.65 M
What is the all time high quarterly EBITDA for Kezar Life Sciences?
Kezar Life Sciences all-time high quarterly EBITDA is -$1.84 M
What is Kezar Life Sciences quarterly EBITDA year-on-year change?
Over the past year, KZR quarterly EBITDA has changed by $0.00 (0.00%)
What is Kezar Life Sciences TTM EBITDA?
The current TTM EBITDA of KZR is -$93.11 M
What is the all time high TTM EBITDA for Kezar Life Sciences?
Kezar Life Sciences all-time high TTM EBITDA is -$2.21 M
What is Kezar Life Sciences TTM EBITDA year-on-year change?
Over the past year, KZR TTM EBITDA has changed by $0.00 (0.00%)